Scalp Hair Regrowth in Hormone-Treated Transgender Woman.

Transgend Health

Center for Transgender Medicine and Surgery, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts.

Published: October 2016

Evidence of androgenetic alopecia, or male pattern baldness, can be distressing for transgender women. Here we present the case of a transgender woman with scalp hair regrowth after ∼6 months on oral estradiol and spironolactone therapy achieving testosterone levels within normal female range.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367483PMC
http://dx.doi.org/10.1089/trgh.2016.0022DOI Listing

Publication Analysis

Top Keywords

scalp hair
8
hair regrowth
8
transgender woman
8
regrowth hormone-treated
4
hormone-treated transgender
4
woman evidence
4
evidence androgenetic
4
androgenetic alopecia
4
alopecia male
4
male pattern
4

Similar Publications

Objective: To assess the clinical efficacy of combining autologous fat grafting with hair follicle unit transplantation.

Methods: The authors conducted a retrospective analysis involving 30 patients at the Department of Plastic Surgery, Second Affiliated Hospital of Nanchang University, between January 2021 and January 2023. Granular fat was harvested from the thigh's posterior aspect using liposuction.

View Article and Find Full Text PDF

Ritlecitinib is an oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma (JAK3/TEC) family kinase inhibitor approved for the treatment of severe alopecia areata (AA). Benefit-risk profiles of two doses of ritlecitinib (50 mg vs 30 mg once daily) were evaluated by integrating patient preferences and clinical efficacy and safety estimates for ritlecitinib. A discrete-choice experiment (DCE) was utilized to elicit preferences for benefit and safety attributes of systemic AA treatments.

View Article and Find Full Text PDF

Phototoxic reaction to oral terbinafine due to Tinea capitis in a child.

Acta Dermatovenerol Croat

November 2024

Prof. Ana Bakija-Konsuo, MD, PhD, Clinic for Dermatovenerology CUTIS, Vukovarska 22, Dubrovnik, Croatia;

We report the case of an 18-month-old boy who developed a phototoxic skin reaction to terbinafine on his scalp, ears, and face in the form of disseminated erythematous plaques, which resembled subacute lupus erythematosus (SCLE) in their clinical presentation. Skin changes appeared a short time after the boy was exposed to sunlight during the period of time when he was treated with oral terbinafine due to Microsporum canis fungal scalp infection. Tinea capitis is a common dermatophyte infection primarily affecting prepubertal children (1).

View Article and Find Full Text PDF

Background Cosmetics have become an integral part of the contemporary lifestyle. Contact dermatitis (CD) is an inflammatory skin disease resulting from exposure to an external chemical present in cosmetics. A patch test is considered the criterion standard method for detecting CD.

View Article and Find Full Text PDF

Direct reprogramming of human fibroblasts into hair-inducing dermal papilla cell-like cells by a single small molecule.

Biochem Pharmacol

January 2025

Department of Anesthesiology, Shenzhen Children's Hospital, Yitian Road 7019, Shenzhen 518000, China. Electronic address:

Dermal papilla cells (DPCs) are a crucial subset of mesenchymal cells in the skin responsible for regulating hair follicle development and growth, making them invaluable for cell-based therapies targeting hair loss. However, obtaining sufficient DPCs with potent hair-inducing abilities remains a persistent challenge. In this study, the Food and Drug Administration (FDA)-approved drug library was utilized to screen small molecules capable of reprogramming readily accessible human skin fibroblasts into functional DPCs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!